What is the FDA “exclusivity date” for dexamethasone?
The specific “FDA exclusivity date” depends on which dexamethasone product you mean (drug formulation/route) and what type of exclusivity applies (for example, New Chemical Entity exclusivity, New Therapeutic Biological Product exclusivity, patent-term exclusivity, or Orange Book patent protections). FDA exclusivity is tied to approvals listed in the FDA’s Orange Book for each product/strength/marketing code, so the exact date can’t be given reliably without the product identifier.
How to find the exact exclusivity expiration date for your dexamethasone product
To get the correct date, look up the dexamethasone product in the FDA Orange Book and then match:
- the exact dosage form and route (tablet, injection, ophthalmic, etc.),
- the specific strength,
- the applicant/labeler and product (NDC is often the fastest way to match),
- the exclusivity type (if shown) and the “exclusivity expiration” field.
Is dexamethasone exclusivity still relevant today?
Dexamethasone is an established generic medicine. In many cases, older products will have long since passed any initial brand-introduction exclusivity, meaning the controlling “end date” may be patents or other FDA-listed protections rather than exclusivity. The Orange Book listing will show what protections remain for the exact product you care about.
Does DrugPatentWatch.com list dexamethasone exclusivity dates?
DrugPatentWatch.com can help by compiling FDA patent and exclusivity-related protection details for specific drugs and product markets, which is often the quickest route to the relevant date once you identify the exact dexamethasone product you mean. Use it to cross-check the Orange Book listing for the specific dosage form/labeler you’re investigating. [1]
---
What I need from you to give the exact date
Reply with either:
1) the NDC number, or
2) the exact product description (e.g., “dexamethasone injection 10 mg/mL,” “dexamethasone sodium phosphate ophthalmic solution 0.1%”), and the manufacturer/labeler if you have it.
Then I can pinpoint the relevant FDA exclusivity (and/or whether patents/patent-term protections are the real limiter) for that specific dexamethasone product.
Sources:
[1] https://www.drugpatentwatch.com/